The endothelium and thrombotic risk in heart failure

• References

• 1 White R. The epidemiology of venous thromboembolism. Circulation 2003; 107: 4-8.
• 2 Dries DL, Rosenberg YD, Waclawiw MA. et al. Ejection fraction and risk of thromboembolic events in patients with sinus rhythm: evidence of gender difference in the studies of left ventricular dysfunction trial. J Am Coll Cardiol 1997; 29: 1074-1080.
• 3 Pullicino PM, Halperin JL, Thompson JL. Stroke in patients with heart failure and reduced left ventricular ejection fraction. Neurology 2000; 25: 288-294.
• 4 Siachos T, Vanbakel A, Feldman DS. et al. Silent strokes in patients with heart failure. J Card Fail 2005; 11: 485-489.
• 5 Dotsenko O, Kakkar VV. Antithrombotic therapy in patients with chronic heart failure: rationale, clinical evidence and practical implications. J Thromb Haemost 2007; 05: 224-231.
• 6 Uretsky BF, Thygesen K, Armstrong PW. et al. Acute coronary findings at autopsy in heart failure patients with sudden death: results from the assessment of treatment with lisinopril and survival (ATLAS) trial. Circulation 2000; 102: 611-616.
• 7 Yusuf S, Pepine CJ, Garces C. et al. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. Lancet 1992; 340: 1173-1178.
• 8 Marcucci R, Gori AM, Giannotti F. et al. Markers of hypercoagulability and inflammation predict mortality in patients with heart failure. J Thromb Haemost 2006; 04: 1017-1022.
• 9 Jafri SM, Mammen EF, Masura J. et al. Effects of warfarin on markers of hypercoagulability in patients with heart failure. Am Heart J 1997; 134: 27-36.
• 10 Massie BM, Collins JF, Ammon SE. et al. Randomized trial of warfarin, aspirin, and clopidogrel in patients with chronic heart failure: the Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) trial. Circulation 2009; 119: 1616-1624.
• 11 Chung I, Lip GY. Platelets and heart failure. Eur Heart J 2006; 27: 2623-2631.
• 12 Celik S, Langer H, Stellos K. et al. Platelet-associated LIGHT (TNFSF14) mediates adhesion of platelets to human vascular endothelium. Thromb Haemost 2007; 98: 798-805.
• 13 Zimmerman GA, McIntyre TM, Mehra M. et al. Endothelial cell-associated platelet-activating factor: A novel mechanism for signaling intercellular adhesion. J Cell Biol 1990; 110: 529-540.
• 14 Chung I, Choudhury A, Lip GY. Platelet activation in acute, decompensated congestive heart failure. Thromb Res 2007; 120: 709-713.
• 15 Schafer A, Schulz C, Eigenthaler M. et al. Novel role of the membrane-bound fractalkine in platelet activation and adhesion. Blood 2004; 103: 407-412.
• 16 Jug B, Vene N, Salobir BG. et al. Prognostic impact of haemostatic derangements in chronic heart failure. Thromb Haemost 2009; 314-320.
• 17 Hristov M, Zernecke A, Liehn EA. et al. Regulation of endothelial progenitor cell homing after arterial injury. Thromb Haemost 2007; 98: 274-277.
• 18 Shantsila E, Watson T, Lip GY. Endothelial progenitor cells in cardiovascular disorders. J Am Coll Cardiol 2007; 49: 741-752.
• 19 Muldowney 3rd JA, Painter CA, Sanders-Bush E. et al. Acute tissue-type plasminogen activator release in human microvascular endothelial cells: the roles of Galphaq, PLC-beta, IP3 and 5,6-epoxyeicosatrienoic acid. Thromb Haemost 2007; 97: 263-271.
• 20 Bajaj MS, Kuppuswamy MN, Manepalli AN. et al. Transcriptional expression of tissue factor pathway inhibitor, thrombomodulin and von Willebrand factor in normal human tissues. Thromb Haemost 1999; 82: 1047-1052.
• 21 Jacquemin M, Neyrinck A, Hermanns MI. et al. FVIII production by human lung microvascular endothelial cells. Blood 2006; 108: 515-517.
• 22 Han KH, Lim JM, Kim WY. et al. Expression of endothelial nitric oxide synthase in developing rat kidney. Am J Physiol Renal Physiol 2005; 288: F694-F702.
• 23 Esmon CT. Thrombomodulin as a model of molecular mechanisms that modulate protease specificity and function at the vessel surface. FASEB J 1995; 09: 946-55.
• 24 Balarajan R. Ethnicity and variations in mortality from coronary heart disease. Health Trends 1996; 28: 45-51.
• 25 Dries DL, Exner DV, Gersh BJ. et al. Racial differences in the outcome of left ventricular dysfuncton. N Engl J Med 1999; 340: 609-616.
• 26 Galasko GI, Senior R, Lahiri A. Ethnic differences in the prevalence and aetiology of left ventricular systolic dysfunction in the community: the Harrow heart failure watch. Heart 2005; 91: 595-600.
• 27 Periaswamy R, Gurusamy U, Shewade DG. et al. Gender specific association of endothelial nitric oxide synthase gene (Glu298Asp) polymorphism with essential hypertension in a south Indian population. Clin Chim Acta 2008; 395: 134-136.
• 28 Koshy L, Easwer HV, Neetha NV. et al. Role of endothelial nitric oxide synthase gene polymorphisms in predicting aneurysmal subarachnoid hemorrhage in South Indian patients. Dis Markers 2008; 24: 333-339.
• 29 Murphy C, Kanaganayagam GS, Jiang B. et al. Vascular dysfunction and reduced circulating endothelial progenitor cells in young healthy UK South Asian men. Arterioscler Thromb Vasc Biol 2007; 27: 936-942.
• 30 Misra A. C-reactive protein in young individuals: problems and implications for Asian Indians. Nutrition 2004; 20: 478-481.